Anlon Healthcare FY26 Results: ₹172 Cr Revenue, ₹29 Cr Profit

Board meeting outcome filed with exchanges

Anlon Healthcare informed the exchange about the outcome of its board meeting held on Wednesday, July 01, 2026. The filing asked market participants to take the information on record, continuing the company’s pattern of formal disclosures around board decisions and financial results. Separately, the company had also attached the outcome of a board meeting held on Friday, May 29, 2026. The May meeting was linked to the company’s audited financial results for the quarter and financial year ended March 31, 2026, along with the auditors’ report. These updates are part of the standard disclosure cycle for listed companies and help investors track corporate actions, results, and capital allocation decisions.

May 29 board agenda: audited results and auditor’s report

Ahead of the May 29, 2026 meeting, Anlon Healthcare told BSE that its board would consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company also noted that the meeting could take up other business with the chair’s permission. The disclosure anchors the FY26 numbers that were later highlighted as being approved by the board. Such board meetings typically culminate in outcome filings, including key financial figures and any material decisions taken alongside results.

FY26 consolidated performance approved by the board

According to the provided information, Anlon Healthcare’s board approved consolidated FY26 results with revenue of ₹171.97 crore and net profit of ₹29.09 crore. These numbers were presented as FY26 consolidated figures, and they form the core financial update in the company’s disclosures. Alongside reporting performance, the board also approved a specific use of IPO proceeds. The company said it would allocate ₹23.33 crore from IPO proceeds for strategic acquisitions, mergers, and manufacturing upgrades.

IPO proceeds allocation: acquisitions, mergers, and upgrades

The board-approved allocation of ₹23.33 crore from IPO proceeds was described as being directed to strategic acquisitions, mergers, and manufacturing upgrades. The information does not provide a project-by-project split, but it clearly outlines the categories for deployment. For investors, this type of disclosure is relevant because it connects fund-raising to operating priorities. It also indicates that, along with reporting audited results, the company is focusing on inorganic opportunities and capacity or capability improvements through manufacturing upgrades.

Guidance and commentary referenced in the provided text

The material also includes revenue guidance commentary for FY26 of ₹170-₹180 crore, and for FY27 of ₹370-₹380 crore. In addition, it references a planned organic expansion greenfield project with capex of around ₹100-₹120 crore. Another section cites revenue expectations of ₹160-₹170 crore from “Enlon” and an additional ₹20-₹25 crore from “APQ”, with a consolidated level mentioned as “somewhere around ₹190-₹200 crore.” The text also notes an acquisition reference, stating expectations of ₹75-₹80 crore from “bizotic.” These items appear as guidance and business commentary in the provided content and are presented here as stated, without adding assumptions beyond the figures given.

Share price snapshots mentioned across dates

Multiple price points are cited in the provided information. Anlon Healthcare was stated to be trading at 15.08 as on Fri Jun 12 2026 10:27:42. Another line states the share price is ₹16.27 as of 24 Jun, 2026. Separately, the text says the stock moved up by 4.00% from its previous close of Rs 139.79, with the last traded price reported as 145.38. The content does not explain why the quoted levels differ, so they are best read as separate snapshots from different references and dates in the provided material.

Board meeting history and corporate actions cited

The provided data includes a table of corporate events with dates and remarks. It lists “Audited Results” dated 2026-05-29, “Bonus issue & Stock Split” dated 2026-03-06, and “Quarterly Results” dated 2026-02-09. It also notes that the latest board meeting took place on 06 Mar 2026 for the purpose of a bonus issue and stock split. Another entry states a board meeting outcome for Friday, December 05, 2025, which approved development of Butamirate Citrate and Ketoprofen Lysinate and mentioned a postal ballot with remote e-voting from Dec 09, 2025 to Jan 07. These disclosures provide context on the company’s recent actions beyond FY26 results.

Key facts table

Timeline of dated disclosures and events

Company contact and registered address cited

The provided content includes the company’s address and contact details. The address is listed as 101/102, Silvercoin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot, Gujarat - 360005. A telephone number is provided as 0281-2562538, and the email is cs@anloncro.com. These details appear in the disclosure-style text and are included as part of the factual information presented.

Market impact: what the disclosed numbers and decisions signal

The market-relevant datapoints in the provided information are the FY26 consolidated revenue and profit, and the board-approved use of IPO proceeds. The FY26 consolidated revenue of ₹171.97 crore and net profit of ₹29.09 crore provide a clear audited benchmark for investors tracking performance. The ₹23.33 crore allocation from IPO proceeds indicates planned capital deployment toward acquisitions, mergers, and manufacturing upgrades, which are typically considered material when they can affect business scale or operating capability. Share-price references in the content show that the stock had reported moves and different price snapshots across June, although the text does not link these moves to specific announcements.

Analysis: why the board outcome matters for investors

Board outcomes matter because they combine audited financial disclosure with capital allocation decisions. Here, the combination of FY26 consolidated results and the stated use of IPO proceeds provides two key inputs: performance and direction. The additional commentary in the provided text, including revenue guidance ranges and capex plans, outlines how the company or its representatives discussed growth and expansion. Since the content does not include further operational details, the main takeaway remains the board-approved FY26 numbers and the clearly stated categories for IPO proceeds usage.

Conclusion

Anlon Healthcare’s recent disclosures highlight board approvals around FY26 consolidated performance and a defined allocation of IPO proceeds toward acquisitions, mergers, and manufacturing upgrades. The dated list of events also shows the company’s recent corporate actions, including a bonus issue and stock split in March 2026. The next steps signaled in the provided text are procedural: exchange filings of board outcomes and result-related disclosures following board meetings held on May 29, 2026 and July 01, 2026.